NEW YORK (GenomeWeb) – Bioinformatics firm N-of-One today announced an agreement with NeoGenomics to interpret the results of tests performed by the cancer genetics diagnostics firm.

Under the agreement, Lexington, Mass.-based N-of-One will provide clinical and interpretive evidence for NeoGenomics' NeoType solid tumor NGS tests, which report the most common and actionable genomic abnormalities in various subtypes of solid tumors.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.